AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10424912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous oral hydration (20 mL/kg)
Number of subjects: 35
Study 7593492 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-I concentrations
Number of subjects: 0
Study 7593492 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular IGF-I concentrations
Number of subjects: 0
Study 7593492 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral circulation IGF-I concentrations
Number of subjects: 0
Study 7593492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian circulation IGF-I concentrations
Number of subjects: 0
Study 1602947 — intervention group
Group type: EXPERIMENTAL
Intervention: High potency multivitamin-mineral supplement
Number of subjects: 22
Study 1602947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6147790 — intervention group
Group type: EXPERIMENTAL
Intervention: Febarbamat
Number of subjects: 0
Study 6147790 — intervention group
Group type: COMPARATOR
Intervention: Pipamperon
Number of subjects: 0
Study 30825407 — intervention group
Group type: EXPERIMENTAL
Intervention: FocalPoint GS (FPGS) No Further Review (NFR)
Number of subjects: 45317
Study 30825407 — intervention group
Group type: COMPARATOR
Intervention: Manual screening
Number of subjects: 45317
Study 29288035 — intervention group
Group type: EXPERIMENTAL
Intervention: V3 CRT (implantation of an additional LV lead; n = 43)
Number of subjects: 84
Study 29288035 — intervention group
Group type: COMPARATOR
Intervention: Control (no change; n = 41)
Number of subjects: 84
Study 26670986 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily changing load (DCL)
Number of subjects: 200
Study 26670986 — intervention group
Group type: COMPARATOR
Intervention: Constant load (CL)
Number of subjects: 200
Study 26670986 — intervention group
Group type: COMPARATOR
Intervention: Increasing load (IL)
Number of subjects: 200
Study 26670986 — intervention group
Group type: COMPARATOR
Intervention: Decreasing load (DL)
Number of subjects: 200
Study 23584298 — intervention group
Group type: EXPERIMENTAL
Intervention: vandetanib
Number of subjects: 255
Study 21697819 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional yogurt NY-YP901 (150 ml, twice a day for 8 weeks)
Number of subjects: 101
Study 21697819 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt (twice a day for 8 weeks)
Number of subjects: 101
Study 20205020 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions and SMS
Number of subjects: 155
Study 20205020 — intervention group
Group type: COMPARATOR
Intervention: Implementation intention
Number of subjects: 155
Study 20205020 — intervention group
Group type: COMPARATOR
Intervention: SMS
Number of subjects: 155
Study 20205020 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 155
Study 16889444 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (OFC) 6/25, 6/50, 12/25, or 12/50 mg/day
Number of subjects: 205
Study 16889444 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine titrated to 200 mg/day
Number of subjects: 205
Study 14748761 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (VNR)
Number of subjects: 2441
Study 14748761 — intervention group
Group type: COMPARATOR
Intervention: Control (other chemotherapeutic agents)
Number of subjects: 2441
Study 11251135 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive multimodal analgesia (IV ketorolac 30 mg, intra-articular ropivacaine 0.25% + morphine 2 mg + epinephrine 1:200,000, femoral nerve block with ropivacaine 0.25%) administered 15 minutes before skin incision
Number of subjects: 40
Study 11251135 — intervention group
Group type: COMPARATOR
Intervention: Control group (multimodal analgesia administered immediately after skin closure)
Number of subjects: 40
Study 9264765 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact laser technique
Number of subjects: 100
Study 9264765 — intervention group
Group type: COMPARATOR
Intervention: Non-contact laser technique
Number of subjects: 100
Study 1606393 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (1.2 U/kg/week)
Number of subjects: 7
Study 1606393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3886395 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg plus codeine 60 mg
Number of subjects: 180
Study 3886395 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus codeine 30 mg
Number of subjects: 180
Study 3886395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 29454501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutricia preOp® (800 ml on the night before surgery/400 ml 2-3 h preoperatively)
Number of subjects: 32
Study 29454501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (800 ml on the night before surgery/400 ml 2-3 h preoperatively)
Number of subjects: 32
Study 29032700 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 504
Study 29032700 — intervention group
Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 504
Study 25628268 — intervention group
Group type: EXPERIMENTAL
Intervention: PC+bevacizumab
Number of subjects: 1345
Study 25628268 — intervention group
Group type: COMPARATOR
Intervention: PC
Number of subjects: 1345
Study 25402403 — intervention group
Group type: EXPERIMENTAL
Intervention: MyFitnessPal app (6 months)
Number of subjects: 212
Study 25402403 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 212
Study 22657252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate oral powder (1000 mg, 3000 mg/d for 10 doses)
Number of subjects: 72
Study 22657252 — intervention group
Group type: COMPARATOR
Intervention: Lanthanum carbonate chewable tablet (1000 mg, 3000 mg/d for 10 doses)
Number of subjects: 72
Study 22657252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (oral powder and chewable tablet)
Number of subjects: 72
Study 20212200 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification alone
Number of subjects: 123
Study 20212200 — intervention group
Group type: COMPARATOR
Intervention: Combined phacotrabeculectomy
Number of subjects: 123
Study 20212200 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification alone vs Combined phacotrabeculectomy
Number of subjects: 123
Study 18849849 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics (AP)
Number of subjects: 77
Study 18849849 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (NP)
Number of subjects: 77
Study 15956987 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 372
Study 15956987 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 372
Study 15956987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 11817468 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide bleaching agent with reservoirs
Number of subjects: 0
Study 11817468 — intervention group
Group type: COMPARATOR
Intervention: 15% carbamide peroxide bleaching agent without reservoirs
Number of subjects: 0
Study 10072242 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0)
Number of subjects: 0
Study 8590744 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 8590744 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic or angioplasty therapy
Number of subjects: 0
Study 2405738 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 17201
Study 2405738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 17201
Study 2405738 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 17201
Study 2405738 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 17201
Study 2405738 — intervention group
Group type: EXPERIMENTAL
Intervention: Preanesthetic medication
Number of subjects: 17201
Study 2405738 — intervention group
Group type: COMPARATOR
Intervention: No preanesthetic medication
Number of subjects: 17201
Study 511251 — intervention group
Group type: EXPERIMENTAL
Intervention: Formolized KFD virus vaccine (two doses administered to 1405 individuals)
Number of subjects: 1989
Study 511251 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated individuals (584 individuals)
Number of subjects: 1989
Study 511251 — intervention group
Group type: EXPERIMENTAL
Intervention: Formolized KFD virus vaccine
Number of subjects: 1989
Study 511251 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated individuals
Number of subjects: 1989
Study 31035949 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision (LE)
Number of subjects: 0
Study 31035949 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision (TME)
Number of subjects: 0
Study 28107853 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Pilates exercises (3 times per week for 6 weeks)
Number of subjects: 40
Study 28107853 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention, usual daily activities)
Number of subjects: 40
Study 26051567 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy with 2% lavender essential oil for 20 min
Number of subjects: 60
Study 26051567 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 60
Study 24016218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 fortified food (1.4 μg/day)
Number of subjects: 351
Study 24016218 — intervention group
Group type: COMPARATOR
Intervention: Control (no complementary food)
Number of subjects: 351
Study 24016218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 351
Study 21235333 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antimicrobials (500 mg amoxicillin + 250 mg metronidazole; three times a day for 10 days)
Number of subjects: 35
Study 21235333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19660681 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS prophylaxis during initial treatment for aggressive NHL
Number of subjects: 0
Study 19660681 — intervention group
Group type: COMPARATOR
Intervention: Current practice variations in CNS prophylaxis
Number of subjects: 0
Study 17339867 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 0
Study 17339867 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg twice daily
Number of subjects: 0
Study 17339867 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily
Number of subjects: 0
Study 17339867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15475132 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot condition
Number of subjects: 8
Study 15475132 — intervention group
Group type: COMPARATOR
Intervention: Shod condition
Number of subjects: 8
Study 11476020 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified version of Serpientes y Escaleras (Snakes and Ladders) with health messages
Number of subjects: 300
Study 11476020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no modified game)
Number of subjects: 300
Study 9794055 — intervention group
Group type: EXPERIMENTAL
Intervention: Back belt
Number of subjects: 24
Study 9794055 — intervention group
Group type: COMPARATOR
Intervention: No back belt (control)
Number of subjects: 24
Study 8790569 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (2.5 MIU m-2, 5.0 MIU m-2, 10.0 MIU m-2) three times weekly by intramuscular injection for 12-24 weeks
Number of subjects: 238
Study 8790569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 238
Study 8790569 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (2.5 MIU m-2)
Number of subjects: 238
Study 8790569 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (5.0 MIU m-2)
Number of subjects: 238
Study 8790569 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a (10.0 MIU m-2)
Number of subjects: 238
Study 8790569 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a
Number of subjects: 238
Study 3185895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training procedures relevant to right hemisphere mechanisms
Number of subjects: 0
Study 3185895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training procedures relevant to left hemisphere mechanisms
Number of subjects: 0
Study 30503831 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT) consisting of basal detemir and premeal insulin aspart
Number of subjects: 24
Study 30503831 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT)
Number of subjects: 24
Study 28365377 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented home exercise programme with Nordic poles
Number of subjects: 61
Study 28365377 — intervention group
Group type: COMPARATOR
Intervention: Normal walking (Control)
Number of subjects: 61
Study 28365377 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented home exercise programme (observational cohort)
Number of subjects: 61
Study 25395350 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g oral glucose
Number of subjects: 240
Study 25395350 — intervention group
Group type: COMPARATOR
Intervention: 100 g standard noodle
Number of subjects: 240
Study 23664707 — intervention group
Group type: EXPERIMENTAL
Intervention: HAA (homoharringtonine 2 mg/m² per day on days 1-7, cytarabine 100 mg/m² per day on days 1-7, and aclarubicin 20 mg/day on days 1-7)
Number of subjects: 620
Study 23664707 — intervention group
Group type: EXPERIMENTAL
Intervention: HAD (homoharringtonine 2 mg/m² per day on days 1-7, cytarabine 100 mg/m² per day on days 1-7, and daunorubicin 40 mg/m² per day on days 1-3)
Number of subjects: 620
Study 23664707 — intervention group
Group type: COMPARATOR
Intervention: DA (daunorubicin 40-45 mg/m² per day on days 1-3 and cytarabine 100 mg/m² per day on days 1-7)
Number of subjects: 620
Study 23664707 — intervention group
Group type: EXPERIMENTAL
Intervention: HAA
Number of subjects: 620
Study 23664707 — intervention group
Group type: EXPERIMENTAL
Intervention: HAD
Number of subjects: 620
Study 23664707 — intervention group
Group type: COMPARATOR
Intervention: DA
Number of subjects: 620
Study 21287804 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 0
Study 21287804 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 0
Study 18063399 — intervention group
Group type: EXPERIMENTAL
Intervention: LTB019
Number of subjects: 24
Study 18063399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15580349 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day)
Number of subjects: 50
Study 15580349 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg/week)
Number of subjects: 50
Study 15580349 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 50
Study 12841703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometrine
Number of subjects: 60
Study 12841703 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 60
Study 10498385 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg Aspirin
Number of subjects: 57
Study 10498385 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Pycnogenol
Number of subjects: 57
Study 10498385 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg Pycnogenol
Number of subjects: 57
Study 10498385 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Pycnogenol
Number of subjects: 57
Study 8698504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent PorA outer membrane vesicle vaccine (50 or 100 micrograms)
Number of subjects: 0
Study 8698504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent PorA outer membrane vesicle vaccine
Number of subjects: 0
Study 2069220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriostatic saline flush solution
Number of subjects: 0
Study 2069220 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline flush solution
Number of subjects: 0
Study 6897123 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg atropine intravenously
Number of subjects: 10
Study 6897123 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pirenzepine intravenously
Number of subjects: 10
Study 6897123 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg pirenzepine perorally twice daily for 4 days
Number of subjects: 10
Study 6897123 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg L-hyoscyamine perorally twice daily for 4 days
Number of subjects: 10
Study 31742707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial translucency (IT) below the fifth percentile
Number of subjects: 27
Study 31742707 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem to brainstem-occipital bone distance (BS/BSOB) above the 95th percentile
Number of subjects: 27
Study 31742707 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillo-occipital (MO) line abnormality
Number of subjects: 27
Study 31742707 — intervention group
Group type: EXPERIMENTAL
Intervention: Biparietal diameter (BPD) below the fifth percentile
Number of subjects: 27
Study 31742707 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD to abdominal circumference ratio (BPD/AC) below the fifth percentile
Number of subjects: 27
Study 31742707 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueduct to occipital bone (AoS) distance below the fifth percentile
Number of subjects: 27
Study 31513234 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory Anesthetic Device ON (VAD ON)
Number of subjects: 87
Study 31513234 — intervention group
Group type: COMPARATOR
Intervention: Vibratory Anesthetic Device OFF (VAD OFF)
Number of subjects: 87
Study 31513234 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD ON
Number of subjects: 87
Study 28679559 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 6935
Study 28679559 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin A1c in DM subgroup
Number of subjects: 6935
Study 28679559 — intervention group
Group type: COMPARATOR
Intervention: Prediabetes Mellitus (pre-DM)
Number of subjects: 6935
Study 25185521 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive preperitoneal (MIP) single-layer mesh repair
Number of subjects: 220
Study 25185521 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein hernia repair (LHR)
Number of subjects: 220
Study 22631626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
Number of subjects: 41
Study 22631626 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (1.0 mg/kg) (MS)
Number of subjects: 41
Study 22631626 — intervention group
Group type: COMPARATOR
Intervention: No sedative (PS)
Number of subjects: 41
Study 21482613 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention group
Number of subjects: 200
Study 21482613 — intervention group
Group type: COMPARATOR
Intervention: In-person counseling group (Control)
Number of subjects: 200
Study 19492920 — intervention group
Group type: EXPERIMENTAL
Intervention: McDonald cerclage
Number of subjects: 79
Study 19492920 — intervention group
Group type: COMPARATOR
Intervention: 17 alpha-hydroxyprogesterone caproate (17OHP-C)
Number of subjects: 79
Study 16456216 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OROS-MPH)
Number of subjects: 147
Study 16456216 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (IR-MPH)
Number of subjects: 147
Study 14745639 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink-related visual input
Number of subjects: 7
Study 14745639 — intervention group
Group type: COMPARATOR
Intervention: No drink-related visual input
Number of subjects: 7
Study 11692987 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol (1 g intramuscular every 8 hours)
Number of subjects: 166
Study 11692987 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (75 mg intramuscular every 12 hours)
Number of subjects: 166
Study 9408800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0
Study 9408800 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study 9408800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8434332 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive, dynamic back‐muscle exercises
Number of subjects: 150
Study 8434332 — intervention group
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Number of subjects: 150
Study 8434332 — intervention group
Group type: COMPARATOR
Intervention: placebo-control treatment
Number of subjects: 150
Study 3303918 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2-interferon as an intranasal spray
Number of subjects: 53
Study 3303918 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53
Study 3303918 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 53
Study 31342228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 1002
Study 31342228 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 1002
Study 29630112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided 125I radioactive seed interstitial implantation brachytherapy
Number of subjects: 116
Study 29630112 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided 125I radioactive seed interstitial implantation brachytherapy
Number of subjects: 116
Study 29630112 — intervention group
Group type: COMPARATOR
Intervention: Control group (external radiation, systemic chemotherapy or conservative treatment)
Number of subjects: 116
Study 27647071 — intervention group
Group type: COMPARATOR
Intervention: rhGM‐CSF gel
Number of subjects: 366
Study 23881309 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered acceptance and commitment therapy (iACT)
Number of subjects: 67
Study 23881309 — intervention group
Group type: COMPARATOR
Intervention: internet-delivered cognitive behavior therapy (iCBT)
Number of subjects: 67
Study 23881309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both iACT and iCBT
Number of subjects: 67